Investigating the Clinical Cure Rate and the Risk Reduction of Hepatocellular Carcinoma in Chronic HBV Infected Individuals With a Family History of Liver Cancer Using PegIFN α-2b Combined With NA Treatment in a Real-world Study.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 400
- 试验地点
- 4
- 主要终点
- Clinical cure rate
研究概览
简要总结
This is a retrospective prospective, open-label, multicenter clinical study aiming to recruit 400 individuals with a family history of liver cancer to explore the clinical cure rate and the effectiveness, feasibility, and safety of PEGylated interferon α-2b combined with nucleos(t)ide analogues in treating chronic HBV carriers with a family history of liver cancer for reducing the risk of liver cancer occurrence. Patients will enrolled into Group A (Peg-IFNα-2b combined with NA treatment group) or Group B (NA monotherapy group) based on their medication choices. Each group is expected to enroll 200 patients, with all patients followed up to 240 weeks. The dosage, frequency, and duration of treatment with Peg-IFN α-2b and NA will be prescribed by the researchers according to clinical practice and standard treatment protocols.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age18-65 years (inclusive of 18 and 65), no restriction on gender;
- •HBsAg positive history for at least 6 months;
- •Family history of liver cancer [including first-degree and second-degree relatives; first-degree relatives are parents, children, and siblings (same parents), while second-degree relatives are uncles, aunts, grandparents, and great-grandparents; a family history of liver cancer means that one or more first-degree or second-degree relatives have had liver cancer];
- •Planning to or already receiving treatment with Peginterferon alpha-2b in combination with nucleoside (acid) analogs, or receiving nucleoside (acid) analogs treatment alone;
- •Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age);
- •Willing to receive treatment and sign an informed consent form.
排除标准
- •Allergy to interferon;
- •History of using telbivudine for antiviral treatment;
- •ALT(Alanine Aminotransferase) greater than 10 times the upper limit of normal, total bilirubin greater than 2 times the upper limit of normal;
- •Decompensated liver cirrhosis;
- •Neutrophil count < 1.5 x 10^9/L or platelet count < 80 x 10^9/L;
- •Presence of severe lesions in vital organs such as the cardiovascular, pulmonary, renal, brain, and fundus;
- •Those with autoimmune diseases, psychiatric disorders, poorly controlled diabetes, or thyroid dysfunction (hyperthyroidism or hypothyroidism);
- •Confirmed or suspected liver cancer or other malignant tumors;
- •Post-organ transplant or preparing for organ transplantation;
- •Currently using immunosuppressants;
- •Pregnant or planning to become pregnant within 2 years;
- •Alcohol or drug addicts;
- •HIV co-infection;
- •Other conditions deemed unsuitable for interferon use by the attending physician.
研究组 & 干预措施
Peg-IFNα-2b combined with NA
干预措施: Peg-IFNα-2b combined with NA (Drug)
NA monotherapy
干预措施: Nucleotide Analogues (Drug)
结局指标
主要结局
Clinical cure rate
时间窗: through study completion, an average of 24 weeks.
The definition of a cure is: maintaining HBsAg(Hepatitis B surface antigen) negativity (with or without the appearance of anti-HBs), undetectable HBV DNA, normal liver biochemical indices, and improvement in liver tissue lesions after discontinuation of treatment.
Liver cancer incidence rate
时间窗: through study completion, an average of 24 weeks.
次要结局
- The decrease in HBsAg compared to baseline.(through study completion, an average of 24 weeks.)
- HBsAg seroconversion rate(through study completion, an average of 24 weeks.)
- Incidence of abnormal and clinically relevant changes in vital signs(through study completion, an average of 24 weeks.)
- Changes of biomarkers after disease progression-related markers such as HBV DNA quantification compared to baseline.(through study completion, an average of 24 weeks.)
- Incidence of treatment-emergent adverse event (AE)(through study completion, an average of 24 weeks.)
- Incidence of abnormal and clinically relevant changes in laboratory assessments(through study completion, an average of 24 weeks.)
- Incidence of severe acute allergic reactions occurring during treatment.(through study completion, an average of 24 weeks.)